Equillium Reveals Early Safety Data For Itolizumab In Lupus Patients

Equillium Inc EQ announced interim data from the Type A portion of the Phase 1b EQUALISE study in systemic lupus erythematosus (SLE) patients.
Data were presented at the American College of Rheumatology (ACR) annual meeting.
The data showed that itolizumab administration was well tolerated and decreased proteinuria and albuminuria, two key biomarkers of disease risk.
The data showed that for SLE patients with baseline urine protein-to-creatinine ratios (UPCR) over 100 mg/g (N=16) and 200 mg/g (N=6), UPCR 34% and 42% declined, respectively, at Day 57.
In addition, for patients with baseline urine albumin-to-creatinine ratio (UACR) of more than 30 mg/g (N=4), there was a decline of 54% at Day 57.
The Type B portion of the EQUALISE study will evaluate up to 20 newly diagnosed or refractory lupus nephritis patients who will be treated with itolizumab dosed at 1.6 mg/kg SC Q2W for up to 24 weeks.
Related Link: Equillium's Itolizumab Reduces Urine Protein In Lupus Patients.
Price Action: EQ shares are up 0.80% at $6.28 during the market session on the last check Tuesday.